Q3 sales remained modest, while the reported loss was affected by an inventory write-down. Our focus remains on the potential 12-month label extension and progress towards the US market, where the efficacy study is due to start around year-end. We lower our base case to SEK1.6 (1.9), reflecting a higher WACC and updated financing assumptions.
LÄS MER
